Evidence map›Paper›PMID 33023926›Full record

ArticleJournal of the American Society of Nephrology : JASN2020

Slope of Kidney Function and Its Association with Longitudinal Mortality and Cardiovascular Disease among Individuals with CKD.

Paula F Orlandi, Dawei Xie, Wei Yang, Jordana B Cohen, Rajat Deo, Ana C Ricardo, Sarah Schrauben, Xue Wang, L Lee Hamm, Jiang He and 9 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04662723 (Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04662723 phase4recruitingnot on this mapstarted 2023, after this paper: background citation

Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

TypeinterventionalSponsorFondazione SchenaRan2023 to 2028Enrolled878ConditionsGlomerulonephritis, Immunoglobulin A NephropathyArmsCorticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor
3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Paula F OrlandiCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania paulaorlandi66@gmail.com.ORCID 0000-0002-7099-9345
Dawei XieCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Wei YangCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Jordana B CohenCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Rajat DeoCardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania.
Ana C RicardoDepartment of Medicine, University of Illinois at Chicago, Chicago, Illinois.ORCID 0000-0001-8670-3644
Sarah SchraubenCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Xue WangCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
L Lee HammSchool of Medicine, Tulane University School of Medicine, New Orleans, Louisiana.
Jiang HeSchool of Medicine, Tulane University School of Medicine, New Orleans, Louisiana.
James H SondheimerSchool of Medicine, Wayne State University, Detroit, Michigan.ORCID 0000-0002-9538-9682
Krishna KallemDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Raymond TownsendDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Dominic RajSchool of Medicine, George Washington University, Washington, D.C.
Afshin ParsaNational Institutes of Health, Bethesda, Maryland.
Amanda H AndersonCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Harold I FeldmanCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
CRIC Study Investigators
Chronic Renal Insufficiency Cohort (CRIC) Study Investigators

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI JING CHEN · 2016 to 2026
$25.3M
Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI OSWALD, LYNN M · 2002 to 2009
$20.2M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
Limited Competition for the Continuation of the Chronic Renal Insufficiency CohorU01DK061021 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI RAHMAN, MAHBOOB · 2001 to 2025
$17.3M
Prospective Renal Insufficiency Cohort Evaluation:PRICEU01DK060984 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI COHEN, DEBBIE L · 2001 to 2025
$17.0M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR002548NCRR NIH HHS M01 RR016500NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR029879NIDDK NIH HHS K23 DK118198NIDDK NIH HHS L30 DK110819NIDDK NIH HHS R01 DK139225NIDDK NIH HHS R21 DK130018NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U24 DK060990NIGMS NIH HHS P20 GM109036
6 · The paper itself

Abstract

backgroundSlopes of eGFR have been associated with increased risks of death and cardiovascular events in a U-shaped fashion. Poor outcomes in individuals with rising eGFR are potentially attributable to sarcopenia, hemodilution, and other indicators of clinical deterioration.

methodsTo investigate the association between eGFR slopes and risks of death or cardiovascular events, accounting for multiple confounders, we studied 2738 individuals with moderate to severe CKD participating in the multicenter Chronic Renal Insufficiency Cohort (CRIC) Study. We used linear, mixed-effects models to estimate slopes with up to four annual eGFR assessments, and Cox proportional hazards models to investigate the association between slopes and the risks of death and cardiovascular events.

resultsSlopes of eGFR had a bell-shaped distribution (mean [SD], -1.5 [-2] ml/min per 1.73 m

conclusionsIn a cohort of individuals with moderate to severe CKD, we observed steep declines of eGFR were associated with progressively increasing risks of death and cardiovascular events; however, we found no increased risks associated with eGFR improvement. These findings support the potential value of eGFR slopes in clinical assessment of adults with CKD.

Indexed as

AgedCardiovascular DiseasesCohort StudiesFemaleGlomerular Filtration RateHumansMaleMiddle AgedProportional Hazards ModelsRenal Insufficiency, ChronicRisk FactorsSensitivity and SpecificitySurvival Ratecardiovascular eventschronic kidney diseaseepidemiology and outcomesglomerular filtration ratemortality riskrisk factors

Identifiers

PMID33023926
PMCPMC7790212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.